Therapeutic Misconceptions and Weight Outcomes With Semaglutide

Semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, was initially developed for the management of type 2 diabetes. The American Diabetes Association’s Standards of Medical Care in Diabetes—2022 recommended GLP-1 receptor agonists as a first-line therapy for type 2 diabetes, particularly in patients with atherosclerotic cardiovascular disease or obesity (1). In addition to improving glycemic control, semaglutide has been shown to significantly reduce food intake and body weight, leading to its approval for obesity treatment, even in patients without diabetes (2).